U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Parathyroid hormone (PTH) is an 84-amino acid peptide that regulates the function of osteoblasts and osteocytes and is secreted by the parathyroid gland in response to changes in the concentration of extracellular calcium. Parathyroid hormone is approved under the brand name NATPARA as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. It is also available for treatment of postmenopausal osteoporosis in many European countries. Parathyroid hormone is an activator of parathyroid hormone 2 receptor. In addition, was shown, that downregulation of Notch in osteoblasts and osteocytes may represent a mechanism contributing to the anabolic effects of parathyroid hormone in bone.

Originator

Approval Year

2015
472
Targets

Targets

Primary TargetPharmacologyConditionPotency
Parathyroid hormone 2 receptor
1
Target ID: P49190
Gene ID: 5746.0
Gene Symbol: PTH2R
Target Organism: Homo sapiens (Human)
Agonist
2752
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
NATPARA

Approved Use

NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

Launch Date

2015
Palliative
Approved
8583
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies.
2016-04
The effect of parathyroid hormone and teriparatide on fracture healing.
2015-01
Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies.
2013-05-15
Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
2012-03
Parathyroid hormone receptor internalization is independent of protein kinase A and phospholipase C activation.
2001-09
Patents

Patents

US4086196
1
WO1993011785A1
1

Sample Use Guides

In Vivo Use Guide
Initiate NATPARA ((parathyroid hormone) 50 mcg once daily as a subcutaneous njection in the thigh (alternate thigh very day). n patients using active forms of vitamine D decrease the dose of active vitamin D by 50%, if serum calcium is above 7.5 mg/dL. In patients using calcium supplements, maintain calcium supplement dose. Measure serum calcium concentration within 3 to 7 days.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Protein
Created
by admin
on Wed Apr 02 09:06:16 GMT 2025
Edited
by admin
on Wed Apr 02 09:06:16 GMT 2025
Protein Type HORMONE
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
N19A0T0E5J
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PARATHORMONUM
HPUS  
Preferred Name English
PARATHYROID HORMONE
DASH   INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
parathyroid hormone [INN]
Common Name English
NATPAR
Brand Name English
PREOTACT
Brand Name English
PARATHYROID [HSDB]
Common Name English
ALX-1-11
Code English
NATPARA
Brand Name English
Parathyroid hormone [WHO-DD]
Common Name English
PTH
Common Name English
PARATHYROID HORMONE [PURPLE BOOK CDER]
Common Name English
PARATHORMONUM [HPUS]
Common Name English
PARATHYROID HORMONE [USAN]
Common Name English
PARATHYROID HORMONE (RDNA)
EMA EPAR  
Common Name English
PARATHORMONE (HUMAN RECOMBINANT)
Common Name English
PARATHYROID HORMONE [MI]
Common Name English
PARATHYROID HORMONE (RDNA) [EMA EPAR]
Common Name English
rhPTH(1-84)
Common Name English
PARATHYROID HORMONE [MART.]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/13/1210
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
NDF-RT N0000180851
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
NDF-RT N0000011221
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
CFR 21 CFR 862.1545
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
WHO-ATC H05AA03
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
NDF-RT N0000011221
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
EMA ASSESSMENT REPORTS PREOTACT (WITHDRAWN: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
WHO-VATC QH05AA03
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
FDA ORPHAN DRUG 246707
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
Code System Code Type Description
DAILYMED
N19A0T0E5J
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
EVMPD
SUB21634
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108078
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
NCI_THESAURUS
C62555
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
DRUG BANK
DB05829
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
INN
8441
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
CAS
9002-64-6
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
RXCUI
1427222
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY RxNorm
SMS_ID
100000089568
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
USAN
OO-40
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
DRUG CENTRAL
4936
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
MERCK INDEX
m8408
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY Merck Index
FDA UNII
N19A0T0E5J
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
EVMPD
SUB181442
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
IUPHAR
1785
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
MESH
D010281
Created by admin on Wed Apr 02 09:06:16 GMT 2025 , Edited by admin on Wed Apr 02 09:06:16 GMT 2025
PRIMARY
Related Record Type Details
Structure of MAXACALCITOL
INHIBITOR OF RELEASE->TARGET
PARATHYROID HORMONE (1-84) HUMAN RECOMBINANT
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
PARATHYROID HORMONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Molecular Formula CHEMICAL
MOL_WEIGHT:FORMULA CHEMICAL
Volume of Distribution PHARMACOKINETIC
Vdss PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966